TIDMPRTC
RNS Number : 1747O
PureTech Health PLC
05 February 2021
THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR
DISTRIBUTION IN WHOLE OR IN PART IN INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF THAT JURISDICTION.
5 February 2021
PureTech Health plc
PureTech Founded Entity Vor Biopharma Announces Pricing of
Initial Public Offering
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases , is pleased to note that its
Founded Entity, Vor Biopharma, has announced the pricing of its
initial public offering (IPO) of 9,828,017 shares of common stock
at a public offering price of $18.00 per share resulting in gross
proceeds to Vor of approximately $176.9 million, before
underwriting discounts and commissions and offering expenses to be
paid by Vor. The shares are expected to begin trading on the Nasdaq
Global Market under the ticker symbol "VOR" on Friday, February 5,
2021. The offering is expected to close on Tuesday, February 9,
2021, subject to customary closing conditions.
Following the offering, PureTech holds 3,207,200 shares of Vor
common stock.
Vor was co-founded by PureTech and Siddhartha Mukherjee, M.D.,
Ph.D., Associate Professor of Medicine at Columbia University and
Pulitzer Prize-winning author of The Emperor of All Maladies: A
Biography of Cancer.
The full text of the announcement from Vor is as follows:
Vor Biopharma Announces Pricing of Initial Public Offering
CAMBRIDGE, Feb. 5, 2021 - Vor Biopharma (Nasdaq: VOR), a cell
therapy company pioneering engineered hematopoietic stem cell
(eHSC) therapies combined with targeted therapies for the treatment
of cancer, today announced the pricing of its initial public
offering of 9,828,017 shares of its common stock at a price to the
public of $18.00 per share. The gross proceeds to Vor from the
offering, before deducting the underwriting discounts and
commissions and other offering expenses payable by Vor, are
expected to be approximately $176.9 million. In addition, Vor has
granted the underwriters a 30-day option to purchase up to an
additional 1,474,202 shares of its common stock at the initial
public offering price, less the underwriting discounts and
commissions. All of the shares of common stock are being offered by
Vor.
The shares are expected to begin trading on the Nasdaq Global
Market on Friday, February 5, 2021, under the ticker symbol "VOR".
The offering is expected to close on Tuesday, February 9, 2021,
subject to customary closing conditions.
Goldman Sachs and Co. LLC, Evercore ISI, Barclays and Stifel are
acting as joint book-running managers for the offering.
Registration statements relating to the securities being sold in
this offering have been filed with the Securities and Exchange
Commission (SEC) and have become effective. Copies of the
registration statements can be accessed through the SEC's website
at www.sec.gov . This offering is being made only by means of a
prospectus forming part of the effective registration statements
relating to these shares. Copies of the final prospectus may be
obtained, when available, from Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, New
York 10282, via telephone at 1-866-471-2526, or via email at
prospectus-ny@ny.email.gs.com ; Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York,
New York 10055, via telephone at 1-888-474-0200, or via email at
ecm.prospectus@evercore.com ; Barclays Capital Inc., Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, via telephone at 1-888-603-5847, or via email at
Barclaysprospectus@broadridge.com ; or Stifel, Nicolaus &
Company, Incorporated, Attention: Syndicate, One Montgomery Street,
Suite 3700, San Francisco, California 94104, via telephone at
1-415-364-2720, or via email at syndprospectus@stifel.com .
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of, these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Vor Biopharma
Vor Biopharma is a cell therapy company that aims to transform
the lives of cancer patients by pioneering eHSC therapies to create
next-generation, treatment-resistant transplants that unlock the
potential of targeted therapies. By removing biologically redundant
proteins from eHSCs, we design these cells and their progeny to be
treatment-resistant to complementary targeted therapies, thereby
enabling these therapies to selectively destroy cancerous cells
while sparing healthy cells.
Ownership Information and Other Required Disclosures
After giving effect to the IPO, PureTech owns 3,207,200 shares
of common stock representing approximately 9.0% of Vor's
outstanding shares, excluding any exercise of the underwriters'
option to purchase additional 1,474,202 shares.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
as of the date of PureTech's most recently filed Registration
Statement on Form 20-F, was comprised of 24 products and product
candidates, including two that have received FDA clearance and
European marketing authorization. All of the underlying programs
and platforms that resulted in this pipeline of product candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company's
unique insights into the biology of the brain, immune and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our product candidates, our expectations regarding Vor's pricing
of its initial public offering and those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Investors
Allison Mead Talbot
+1 617 651 3156
amt@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKPBBDBKDQBK
(END) Dow Jones Newswires
February 05, 2021 06:46 ET (11:46 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024